       Document 0136
 DOCN  M95A0136
 TI    The safety and use of canarypox vectored vaccines.
 DT    9510
 AU    Plotkin SA; Cadoz M; Meignier B; Meric C; Leroy O; Excler JL; Tartaglia
       J; Paoletti E; Gonczol E; Chappuis G; Pasteur-Merieux Serums et Vaccins,
       Marnes-la Coquette, France.
 SO    Dev Biol Stand. 1995;84:165-70. Unique Identifier : AIDSLINE
       MED/95317468
 AB    ALVAC recombinants have been administered to humans and animals by
       parenteral and oral routes without giving signs of replication, systemic
       dissemination or severe reaction. In principle, it should be impossible
       for canarypox recombinants to disseminate in the environment as they
       would not be synthesised in mammalian cells as complete virus. Canarypox
       vectors have been safe for humans, in whom there has been no evidence of
       replication, but more work needs to be done to prove absence of
       replication. Recombinants are immunogenic by the intramuscular and
       subcutaneous routes. They are also immunogenic when given orally, but
       the dose required is still under study. Canarypox recombinants
       effectively prime the immune system for induction of antibodies and CD8
       cell-mediated cytotoxicity by protein antigens. Antibody responses are
       not influenced by prior inoculation of canarypox, of subunit vaccine
       corresponding to the gene insert, or of vaccinia. Canarypox virus is
       attenuated for canaries, in which species it is already widely used. In
       principle, it is non-infectious for humans or other mammals. It may be
       infectious for other birds.
 DE    Animal  Avipoxvirus/*GENETICS/PHYSIOLOGY  AIDS Vaccines/ADMINISTRATION &
       DOSAGE/GENETICS/PHARMACOLOGY  Genetic Vectors/*ADVERSE
       EFFECTS/PHARMACOLOGY  Human  Rabies Vaccine/ADVERSE
       EFFECTS/GENETICS/PHARMACOLOGY  Safety  Vaccines, Attenuated/ADVERSE
       EFFECTS/GENETICS/PHARMACOLOGY  Vaccines, Synthetic/*ADVERSE
       EFFECTS/*GENETICS/PHARMACOLOGY  Viral Vaccines/ADVERSE
       EFFECTS/GENETICS/PHARMACOLOGY  Virus Replication  JOURNAL ARTICLE

       SOURCE: National Library of Medicine.  NOTICE: This material may be
       protected by Copyright Law (Title 17, U.S.Code).

